Iovance Biotherapeutics's total assets for Q1 2026 were $925.66M, an increase of 1.37% from the previous quarter. IOVA total liabilities were $203.91M for the fiscal quarter, a -4.98% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.